The Neuron Bio Group has over 50 employees including numerous researchers, many of them PhDs who have studied in prestigious public research centers and managers with wide experience in business innovation. Over the 85% of the company staff is directly involved in R&D activities working in different laboratories.
To reinforce even more its scientific excellence the company has also a Scientific Advisory Board made up of important figures such asProfessor Federico Mayor Zaragoza, Professor Ana Frank-García, Professor Arnold L. Demain, Dr. Jesús Benavides and Dr. Miguel A. Moreno.
Management Team
Chairman: Prof. Fernando Valdivieso
E-mail: [email protected]
Dr. Valdivieso was awarded his Ph.D. in Chemistry at the University of Granada. He is professor of Biochemistry and Molecular Biology at the Autonomous University of Madrid and head of the Laboratory of Neurovirology at the Severo Ochoa Molecular Biology Centre (CSIC-UAM). Dr. Valdivieso was once visiting professor at Yale University and at the University of San Diego, California. He has also been Director of the Molecular Biology Institute, Director of the Department of Molecular Biology and Dean of the Faculty of Sciences at the UAM and General Research Manager at the Spanish Ministry of Science and Technology. He has been a member of the Board of Directors of various biotech companies and of the Spanish Centre for Industrial Technological Development (CDTI). Dr. Valdivieso has been a member of the Madrid Bioethics Advisory Committee. During his scientific career he has carried out research on the molecular basis for neurotransmission and since 1987 on the molecular pathology of Alzheimer’s disease. He has published more than 100 papers in prestigious international scientific journals and has also contributed to international scientific books. He holds several patents in the field of diagnosis and treatment of Alzheimer’s disease.
Chief Executive Officer: Javier S. Burgos Muñoz, Ph.D.
E-mail: [email protected]
Former CSO of the Neuron BioPharma Division, Dr. Burgos was awarded a Ph.D. in Biology at the Autonomous University of Madrid and holds a degree in biology from the University of Valencia. He remained at the Autonomous University of Madrid as a lecturer and research scientist in the Department of Molecular Biology. Dr. Burgos was also a guest researcher at the Keck School of Medicine at the University of Southern California (USA), as well as at the Instituto de Ciencias Básicas de la Salud (Federal University of Rio Grande do Sul, Brazil). Author of more than 40 scientific papers in international journals and contributed to several chapters in scientific books. Dr. Burgos is co-inventor of 8 patents in the field of diagnosis and treatment of Alzheimer’s disease and has also directed various doctoral theses in the field of the Alzheimer’s disease etiology. He is a member of the editorial committees of journals such as Journal of Alzheimer’s Disease, American Journal of Neurodegenerative Disease and Journal of Viruses.
Chief Scientific Officer (CSO): Soraya Santana
E-mail: [email protected]
Dr. Santana was awarded her Ph.D. in Molecular Biology and holds a degree in biology from the Autonomous University of Madrid (UAM). She has been researcher of the UAM Department of Molecular Biology and of the hospital Hospital Universitario de La Paz. Dr. Santana has been lecturer of the University of Granada and also of the Autonomous University of Madrid. She is part of the Neuron Bio team since 2011, where she has been head of the scientific zebrafish platform and of the preclinical services for clients. She has published various scientific papers in international journals and is co-inventor of four patents in the field of diagnosis and treatment of Alzheimer’s disease.
Chief Financial Officer (CFO): Antonio Sánchez Torres.
E-mail: [email protected]
Sánchez holds a B.Sc. in Law and Business Studies from the University Pontificia de Comillas (ICADE) and also holds a Masters degree in Advanced Management Program from Instituto de Empresa (IE) in Andalucía 2007. His career started in Deloitte carrying out audit work and other activities in different sectors (financial, services, production, etc.). He has worked in the financial department of various companies of the real estate sector (Comarex, FRAI, Grupo Nuovit).
Chief Commercial Officer (CCO): James Webb
E-mail: [email protected]
Graduate of Biochemistry from Heriot Watt University (UK) , Master in Molecular Genetics , University of Leicester (UK ), Executive Master in Business Administration from the Instituto de Empresa ( IE Business School, Madrid)) with a specialization in Entrepreneurship and Innovation. James began his career working as a clinical researcher in the field of Fragile X and is an author and contributor to several scientific papers in international journals. He left clincial science to lead teams in the area of IT , HR, Marketing , Sales and Competitive Intelligence in the financial sector before entering the biotechnology industry where he has participated in the launch of five pioneering products in the field of rare diseases.
James has collaborated with groups in the European Union for the promotion and business coaching of start ups in the Healthcare area in Spain, Europe and Israel.
